PRFX vs. GLMD, PBLA, WINT, BON, ONCT, SXTC, ADTX, PTEIQ, TRVN, and TNFA
Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Galmed Pharmaceuticals (GLMD), Panbela Therapeutics (PBLA), Windtree Therapeutics (WINT), Bon Natural Life (BON), Oncternal Therapeutics (ONCT), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), PolarityTE (PTEIQ), Trevena (TRVN), and TNF Pharmaceuticals (TNFA). These companies are all part of the "pharmaceutical products" industry.
PainReform vs.
PainReform (NASDAQ:PRFX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
PainReform has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
37.3% of PainReform shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Galmed Pharmaceuticals received 439 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 63.41% of users gave Galmed Pharmaceuticals an outperform vote.
Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
In the previous week, PainReform had 4 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 5 mentions for PainReform and 1 mentions for Galmed Pharmaceuticals. PainReform's average media sentiment score of 0.63 beat Galmed Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the media.
PainReform presently has a consensus target price of $8.00, suggesting a potential upside of 153.16%. Given PainReform's stronger consensus rating and higher probable upside, equities research analysts plainly believe PainReform is more favorable than Galmed Pharmaceuticals.
Galmed Pharmaceuticals' return on equity of -28.75% beat PainReform's return on equity.
Summary
PainReform and Galmed Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get PainReform News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PainReform Competitors List
Related Companies and Tools
This page (NASDAQ:PRFX) was last updated on 2/22/2025 by MarketBeat.com Staff
